Medical/Pharmaceuticals

Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa

MUMBAI, India, Dec. 15, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East andAfrica (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. This accolade is a testament to the success of the company's flagship liquid biopsy, the Guardan...

2020-12-15 11:00 1562

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, Netherlands, Dec. 15, 2020 /PRNewswire/ -- Harbour BioMed (HBM)(HKEX:02142), andUtrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing antibody, 47D11 and program, for the prevention and treatment o...

2020-12-15 08:00 7579

Otto Damsma Joins Bioforum as Vice President of Asia Pacific Operations

Bioforum Bolsters Leadership Team to Drive Expansion in Australia and Asia Pacific Region NESS ZIONA, Israel, Dec. 15, 2020 /PRNewswire/ -- Bioforum , a global data-focused contract research organization (CRO), today announced the appointment ofOtto Damsma as Vice Pr...

2020-12-15 05:00 1814

Regent Pacific's Commercial Strategic Partner Receives Approval from Taiwan Food and Drug Administration

HONG KONG, Dec. 14, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Orient EuroPharma Co., L...

2020-12-14 20:20 3973

Canadian pilot study suggests prescription icosapent ethyl (VASCEPA®) might improve symptoms of COVID-19 and reduce inflammation

TORONTO, ON, Dec. 14, 2020 /PRNewswire/ -- The results of a Canadian study released this weekend provides encouraging data suggesting that the prescription strength omega-3 called icosapent ethyl (VASCEPA) may reduce inflammation and improve symptoms in patients with a diagnosis of COVID-19. "Th...

2020-12-14 20:00 2061

Sai Life Sciences releases its first Sustainability Report

- Developed as per the Global Reporting Initiative (GRI) standards - Highlights the various sustainable choices embraced by the company in steering its journey on a sustainable path HYDERABAD, India, Dec. 14, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Resear...

2020-12-14 18:42 2209

Ortoma launches OTS 5 according to plan

STOCKHOLM, Dec. 14, 2020 /PRNewswire/ -- Ortoma, manufacturer of surgical assistive technology for planning and positioning of implants, launches the latest version of the company's surgical system Ortoma Treatment Solution (OTS), which is based on AI (Artificial Intelligence). Ongoing active mar...

2020-12-14 16:28 1283

Exploring Breast Cancer from a 3-Dimensional Perspective

SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Every October, the streets (and Internet) are rife with various awareness campaigns and pink ribbon projects that boost information on breast cancer and available screening methods. Despite an abundance of information available through mass-distributed br...

2020-12-14 15:31 1443

Molecular Stethoscope Announces Completion and Publication of its Alzheimer's Disease Study in Science Advances

PALO ALTO, Calif., Dec. 14, 2020 /PRNewswire/ -- Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of a human proof-of-concept study for Alzheimer's Disease using its proprietary cell-free messenger RNA (cf-mRNA)-Artificial Intelligence Technology Plat...

2020-12-14 13:00 1320

High prevalence of hospital malnutrition associated with poor clinical outcomes

BAD HOMBURG, Germany, Dec. 14, 2020 /PRNewswire/ -- Hospital malnutrition is documented in many observational studies fromthe United States, Europe, and Latin America. A recently published literature review found that malnutrition is highly prevalent across different hospital patient groups in...

2020-12-14 10:00 1971

Global Respiratory Clinics Market will grow at a CAGR of 20.7% over the forecast period - says Absolute Markets Insights

PUNE, India, Dec. 14, 2020 /PRNewswire/ --   Respiratory Clinics Market will grow at a CAGR of 20.7% * In the United States currently more than 25 million people are diagnosed with asthma, because of thes...

2020-12-14 10:00 2320

Global Respiratory Care Devices Market was Valued at US$ 15527.49 Mn in 2019 Growing at a CAGR of 12.25% over the Forecast Period- says Absolute Markets Insights

PUNE, India, Dec. 14, 2020 /PRNewswire/ -- * The COVID-19 pandemic is expected to have a positive impact on the global respiratory care devices market in the coming years. This is because of the increasin...

2020-12-14 09:00 2221

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked...

2020-12-14 09:00 1914

Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that it received Fast Track designation from the U.S. Food and Drug Administration (F...

2020-12-14 08:30 2841

Kintor Proxalutamide's COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates

SUZHOU, China, Dec. 12, 2020 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Proxalutamide's clinical trial for the treatment of COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutica...

2020-12-12 11:02 12510

BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Not intended for US-, Canada- and UK-based media DARMSTADT, Germany and NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE)  today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion rec...

2020-12-11 21:00 6343

Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial

SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Proxalutamide's clinical trial for COVID-19. Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutical and is currentl...

2020-12-11 19:44 9374

Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer

SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2020-12-11 09:02 7371

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

SHANGHAI and HONG KONG, Dec. 11, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2020-12-11 08:00 5073

European Union Intellectual Property Office Revokes Counterfeiter's Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs

NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed's falsely registered AQUAGOLD® design, originally created and owned by Aquavit. ...

2020-12-11 03:10 2934
1 ... 319320321322323324325 ... 397

Week's Top Stories